Filing Flows

Filing Flows › Insulet (PODD) › Next earnings date

Insulet (PODD) earnings: beat the estimate

Insulet (PODD) reported on Nov 4, 2026 and beat the EPS estimate: $1.99 against $1.59 (+25.4%). Revenue was $842M for Q3 2026, +19% year over year. It beat the EPS estimate in 100% of the quarters on record.

Last result+25.4% vs estimate
Beat rate100%

The last report

Insulet reported revenue of $842M for the third quarter 2026 (+19% Y/Y), net earnings $141M: Total Omnipod products $837M, Drug Delivery $5.5M. How it makes money → · Every quarter →

Insulet: EPS against the estimate, last 5 reportsInsulet: EPS against the estimate, last 5 reportsEstimateReported$1.15$1.24Nov 25$1.46$1.55Feb 26$1.19$1.42May 26$1.45$1.66Aug 26$1.59$1.99Nov 26
Latest (Nov 26): Estimate $1.59, Reported $1.99.
PODD: the stock's move on each reportPODD: the stock's move on each reportAug 5, 2026-16.5%May 6, 2026-4.3%Feb 18, 2026+1.1%Nov 6, 2025+1.7%

Insulet's latest quarter

Insulet, Q3 2026: revenue $842M (+19% year over year), operating margin 22.5%, net earnings $141M, operating cash flow $124M. The chart follows the revenue to costs, profit and cash.

Questions

Did Insulet beat earnings?

Insulet (PODD) reported on Nov 4, 2026 and beat the EPS estimate: $1.99 against $1.59 (+25.4%).

When does PODD report earnings?

The next date is not set yet.

Does Insulet usually beat earnings?

It beat the consensus EPS estimate in 100% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.